Drugs in R & D最新文献

筛选
英文 中文
Change in hematologic indices over time in pediatric inflammatory bowel disease treated with azathioprine. 硫唑嘌呤治疗儿童炎症性肠病血液学指标随时间的变化
IF 3
Drugs in R & D Pub Date : 2010-01-01 DOI: 10.2165/11539930-000000000-00000
Sherman Soman, Dhandapani Ashok, Sally A Connolly, Samantha J Cordell, Chris J Taylor, David I Campbell
{"title":"Change in hematologic indices over time in pediatric inflammatory bowel disease treated with azathioprine.","authors":"Sherman Soman,&nbsp;Dhandapani Ashok,&nbsp;Sally A Connolly,&nbsp;Samantha J Cordell,&nbsp;Chris J Taylor,&nbsp;David I Campbell","doi":"10.2165/11539930-000000000-00000","DOIUrl":"https://doi.org/10.2165/11539930-000000000-00000","url":null,"abstract":"<p><p>Azathioprine leads to changes in mean corpuscular volume (MCV) and white blood cell (WBC) indices reflecting efficacy or toxicity. Understanding the interactions between bone marrow stem cells and azathioprine could highlight abnormal response patterns as forerunners for hematologic malignancies. This study gives a statistical description of factors influencing the relationship between MCV and WBC in children with inflammatory bowel disease treated with azathioprine. We found that leukopenia preceded macrocytosis. Macrocytosis is therefore not a good predictor of leukopenia. Further studies will be necessary to determine the subgroup of patients at increased risk of malignancies based on bone marrow response.</p>","PeriodicalId":11373,"journal":{"name":"Drugs in R & D","volume":" ","pages":"213-7"},"PeriodicalIF":3.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2165/11539930-000000000-00000","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29546707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Clopidogrel resistance is associated with long-term thrombotic events in patients implanted with drug-eluting stents. 氯吡格雷耐药性与植入药物洗脱支架患者的长期血栓事件相关。
IF 3
Drugs in R & D Pub Date : 2010-01-01 DOI: 10.2165/11539580-000000000-00000
Lin Wang, Xiaobei Wang, Fenghua Chen
{"title":"Clopidogrel resistance is associated with long-term thrombotic events in patients implanted with drug-eluting stents.","authors":"Lin Wang,&nbsp;Xiaobei Wang,&nbsp;Fenghua Chen","doi":"10.2165/11539580-000000000-00000","DOIUrl":"https://doi.org/10.2165/11539580-000000000-00000","url":null,"abstract":"<p><strong>Background: </strong>There are limited prospective data on clopidogrel resistance and clinical outcome of patients with selective coronary drug-eluting stent (DES) implantation.</p><p><strong>Objective: </strong>To investigate whether clopidogrel resistance is associated with long-term thrombotic events in patients with selective coronary DES implantation.</p><p><strong>Methods: </strong>A total of 154 patients who underwent selective percutaneous coronary intervention (PCI) with DES were enrolled in this study. Platelet aggregation was measured using light transmittance aggregometry (LTA) before clopidogrel administration (baseline) and 24 hours after loading with clopidogrel 300 mg. Clopidogrel resistance was defined as ≤10% absolute difference between baseline aggregation and post-administration aggregation. All patients who received the same anti-platelet treatment were followed up for 1 year after discharge for the incidence of a composite endpoint consisting of cardiovascular death, myocardial infarction (MI) and revascularization, and secondly for the incidence of stent thrombosis.</p><p><strong>Results: </strong>The incidence of clopidogrel resistance is 20.28% in our study population. Patients who are complicated by diabetes mellitus, smoke, or have a higher body mass index (BMI) tend to have clopidogrel resistance. Patients in the clopidogrel-resistant group have significantly higher incidences of composite endpoints (21.88% vs 4.92%; p = 0.006) and stent thrombosis (12.5% vs 1.64%; p = 0.017) than patients in the clopidogrel-response group during 1-year follow-up.</p><p><strong>Conclusions: </strong>Diabetes, smoking, and high BMI are associated with clopidogrel resistance, and clopidogrel resistance indicates an increased risk of long-term thrombotic events in patients implanted with DES.</p>","PeriodicalId":11373,"journal":{"name":"Drugs in R & D","volume":" ","pages":"219-24"},"PeriodicalIF":3.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2165/11539580-000000000-00000","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29546708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 18
Evaluation of the pharmacokinetic interaction between lesogaberan (AZD3355) and esomeprazole in healthy subjects. 莱索加伯兰(AZD3355)与埃索美拉唑在健康人体内药代动力学相互作用的评价。
IF 3
Drugs in R & D Pub Date : 2010-01-01 DOI: 10.2165/11588180-000000000-00000
Mohammad Niazi, Debra G Silberg, Frank Miller, Magnus Ruth, Ann A Holmberg
{"title":"Evaluation of the pharmacokinetic interaction between lesogaberan (AZD3355) and esomeprazole in healthy subjects.","authors":"Mohammad Niazi,&nbsp;Debra G Silberg,&nbsp;Frank Miller,&nbsp;Magnus Ruth,&nbsp;Ann A Holmberg","doi":"10.2165/11588180-000000000-00000","DOIUrl":"https://doi.org/10.2165/11588180-000000000-00000","url":null,"abstract":"<p><strong>Background: </strong>Transient lower esophageal sphincter relaxations (TLESRs) have been identified as a primary cause of reflux events in patients with gastroesophageal reflux disease (GERD). GABA(B) receptor agonists such as lesogaberan (AZD3355) have been shown to inhibit TLESRs in healthy subjects and patients with GERD, and, therefore, offer a novel therapeutic add-on strategy to acid suppression for the management of GERD. As lesogaberan is being developed as an add-on treatment for the management of patients with GERD who have a partial response to proton pump inhibitor (PPI) therapy, it is important to rule out any clinically important pharmacokinetic drug-drug interaction between lesogaberan and PPIs.</p><p><strong>Objective: </strong>To evaluate the effect of esomeprazole on the pharmacokinetics and safety of lesogaberan and vice versa.</p><p><strong>Study design: </strong>This was an open-label, randomized, three-way crossover study. The study was open to healthy adult male and female subjects. The study subjects received treatment with, in random order, lesogaberan (150 mg twice daily [dose interval 12 hours]), esomeprazole (40 mg once daily), and a combination of both, during 7-day treatment periods.</p><p><strong>Main outcome: </strong>The presence or absence of pharmacokinetic interactions between lesogaberan and esomeprazole was assessed by measuring the steady-state area under the plasma concentration-time curves during the dosing interval (AUC(τ)) and the maximum observed plasma concentration (C(max)) for lesogaberan and esomeprazole.</p><p><strong>Results: </strong>Thirty male subjects (mean age 23.2 years, 97% Caucasian) were randomized to treatment and 28 subjects completed the study (one subject was lost to follow-up, and one subject discontinued due to an adverse event). The 95% confidence intervals of the geometric mean ratios for AUC(τ) and C(max) of lesogaberan and esomeprazole administered alone and concomitantly were within the recognized boundaries of bioequivalence (0.8-1.25). No new safety concerns were raised during this study. The number of patients with adverse events during treatment with lesogaberan alone (n = 17) and concomitantly with esomeprazole (n = 18) were comparable but higher than with esomeprazole alone (n = 10). Paresthesia (episodic, mild, and transient), pharyngitis, and flatulence were the most frequently reported adverse events.</p><p><strong>Conclusions: </strong>There was no observed pharmacokinetic interaction between lesogaberan and esomeprazole when concomitantly administered to healthy subjects, and concomitant therapy was well tolerated. TRIAL REGISTRATION NUMBER (clinicaltrials.gov): NCT00684190.</p>","PeriodicalId":11373,"journal":{"name":"Drugs in R & D","volume":" ","pages":"243-51"},"PeriodicalIF":3.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2165/11588180-000000000-00000","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29546710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
MicroRNA: Potential Targets for the Development of Novel Drugs? MicroRNA:开发新药的潜在靶点?
Drugs in R & D Pub Date : 2010-01-01 DOI: 10.1007/BF03259769
Wei Wu
{"title":"MicroRNA: Potential Targets for the Development of Novel Drugs?","authors":"Wei Wu","doi":"10.1007/BF03259769","DOIUrl":"https://doi.org/10.1007/BF03259769","url":null,"abstract":"","PeriodicalId":11373,"journal":{"name":"Drugs in R & D","volume":"15 1","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79337618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Profile Summary 概要总结
Drugs in R & D Pub Date : 2003-01-01 DOI: 10.2165/00126839-200304020-00004
{"title":"Profile Summary","authors":"","doi":"10.2165/00126839-200304020-00004","DOIUrl":"https://doi.org/10.2165/00126839-200304020-00004","url":null,"abstract":"","PeriodicalId":11373,"journal":{"name":"Drugs in R & D","volume":"120 1","pages":"111"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89868751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Morphine Oral - Elan Corporation 吗啡口服- Elan公司
Drugs in R & D Pub Date : 2002-01-01 DOI: 10.2165/00126839-200203030-00015
{"title":"Morphine Oral - Elan Corporation","authors":"","doi":"10.2165/00126839-200203030-00015","DOIUrl":"https://doi.org/10.2165/00126839-200203030-00015","url":null,"abstract":"","PeriodicalId":11373,"journal":{"name":"Drugs in R & D","volume":"23 1","pages":"208-209"},"PeriodicalIF":0.0,"publicationDate":"2002-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81191408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Profile Summary 概要总结
Drugs in R & D Pub Date : 2002-01-01 DOI: 10.2165/00126839-200203040-00006
{"title":"Profile Summary","authors":"","doi":"10.2165/00126839-200203040-00006","DOIUrl":"https://doi.org/10.2165/00126839-200203040-00006","url":null,"abstract":"","PeriodicalId":11373,"journal":{"name":"Drugs in R & D","volume":"4 1","pages":"257"},"PeriodicalIF":0.0,"publicationDate":"2002-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87609902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IDM 1 IDM 1
Drugs in R & D Pub Date : 2002-01-01 DOI: 10.2165/00126839-200203010-00011
{"title":"IDM 1","authors":"","doi":"10.2165/00126839-200203010-00011","DOIUrl":"https://doi.org/10.2165/00126839-200203010-00011","url":null,"abstract":"","PeriodicalId":11373,"journal":{"name":"Drugs in R & D","volume":"215 1","pages":"50-51"},"PeriodicalIF":0.0,"publicationDate":"2002-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75708339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Triamcinolone Acetonide Hydrofluoroalkane Inhalation —Aventis 氢氟烷烃曲安奈德吸入剂-安万特
Drugs in R & D Pub Date : 2002-01-01 DOI: 10.2165/00126839-200203020-00018
{"title":"Triamcinolone Acetonide Hydrofluoroalkane Inhalation —Aventis","authors":"","doi":"10.2165/00126839-200203020-00018","DOIUrl":"https://doi.org/10.2165/00126839-200203020-00018","url":null,"abstract":"","PeriodicalId":11373,"journal":{"name":"Drugs in R & D","volume":"18 1","pages":"141-142"},"PeriodicalIF":0.0,"publicationDate":"2002-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79243962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oxybutynin Intravesical — Situs 奥昔布宁膀胱内注射
Drugs in R & D Pub Date : 2002-01-01 DOI: 10.2165/00126839-200203020-00002
{"title":"Oxybutynin Intravesical — Situs","authors":"","doi":"10.2165/00126839-200203020-00002","DOIUrl":"https://doi.org/10.2165/00126839-200203020-00002","url":null,"abstract":"","PeriodicalId":11373,"journal":{"name":"Drugs in R & D","volume":"38 1","pages":"82-83"},"PeriodicalIF":0.0,"publicationDate":"2002-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77378148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信